Stay Connected. Stay Informed.
Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for Ascorbic Acid Injection USP, 25,000 mg/50 mL (500 mg/mL), 5,000 mg/10 mL (500 mg/mL). The product, primarily used for the short-term treatment of scurvy, is a generic of reference listed drug Ascor Injection. The…
Read More “Zydus secures U.S. FDA nod for scurvy injection generic” »
“The collaboration marks an important step in strengthening Sri Lanka’s healthcare ecosystem and building sustainable pharmaceutical capabilities for the future,” Zydus Lifesciences managing director Sharvil P. Patel. Photo: Special Arrangement Zydus Lifesciences and Sunshine Healthcare Lanka have formed a joint venture to establish a $20 million pharmaceutical manufacturing facility in Sri Lanka. Foundation stone of…